Viral IL-10 gene transfer prolongs rat islet allograft survival. 2008

Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, 138-736, Korea.

Islet transplantation is a potential cure for diabetes. However, allotransplant rejection severely limits its clinical application. In this study, we sought to transfect rat islets with an adenoviral vector containing the viral IL-10 (vIL-10) gene and examine its efficacy in preventing graft rejection. The immunosuppressive effect of vIL-10 is reported but its efficacy is somehow debatable in transplantation model. vIL-10 transfected islets were transplanted into streptozotocin-induced diabetic rats. Blood glucose, serum vIL-10 concentration, graft histology, and graft cytokine expression were used to monitor graft function up to day 21 after transplantation. Transfected islets released a large amount of vIL-10 protein without affecting their viability and functional integrity. When we transplanted the transfected islets into allogeneic hosts, the survival of grafted islets was not significantly increased. However, the combined use of vIL-10 and subtherapeutic doses of CsA (cyclosporine) significantly prolonged graft survival beyond that achieved with either agent alone (p < 0.001). vIL-10 and CsA-treated rats contain high level of vIL-10 in serum, which is evidenced by the inhibition of allogeneic mixed lymphocyte reaction (MLR). Histological analysis additionally revealed the presence of viable islets up to 21 days. IL-10 mRNA expression in grafted liver was higher and IFN-gamma mRNA was lower in vIL-10 and CsA-treated animals, compared with other groups. The synergistic effect of this combination therapy is potentially correlated with the induction of inhibitory cytokine secretion and downregulation of proinflammatory cytokine secretion from host cells.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008297 Male Males
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006082 Graft Enhancement, Immunologic The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunized donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. Immunologic Enhancement of Grafts,Enhancement, Immunologic Graft,Graft Enhancement,Graft Enhancement, Immunological,Immunologic Graft Enhancement,Enhancement, Graft,Enhancement, Immunological Graft,Enhancements, Graft,Enhancements, Immunologic Graft,Enhancements, Immunological Graft,Graft Enhancements,Graft Enhancements, Immunologic,Graft Enhancements, Immunological,Immunologic Graft Enhancements,Immunological Graft Enhancement,Immunological Graft Enhancements
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections

Related Publications

Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
March 1996, Journal of immunology (Baltimore, Md. : 1950),
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
May 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
January 2000, Transplant international : official journal of the European Society for Organ Transplantation,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
November 2000, Transplantation proceedings,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
August 1998, Gene therapy,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
December 1992, Transplantation proceedings,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
July 2011, Transplantation,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
May 1999, Gene therapy,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
December 2007, American journal of physiology. Heart and circulatory physiology,
Yang-Hee Kim, and Dong-Gyun Lim, and Yu-Mee Wee, and Jin-Hee Kim, and Chae-Ok Yun, and Monica-Y Choi, and Youn-Hee Park, and Song-Cheol Kim, and Duck-Jong Han
December 1999, Transplantation,
Copied contents to your clipboard!